NextCure (NXTC) Capital Expenditures (2018 - 2024)
NextCure (NXTC) posted quarterly Capital Expenditures of -$34000.0 for Q4 2024, down 361.54% year-over-year from $13000.0 in Q1 2024, and down 120.0% quarter-over-quarter from $170000.0 in Q3 2024.
NextCure (NXTC) Capital Expenditures (2018 - 2024) Analysis & Trends
NextCure's Capital Expenditures history runs 7 years deep, the most recent figure standing at -$34000.0 for Q4 2024.
- In Q4 2024, Capital Expenditures fell 361.54% year-over-year to -$34000.0; the TTM figure through Dec 2024 stood at $474000.0 (down 42.2% YoY), while the FY2024 annual figure was $474000.0, down 42.2% from the prior year.
- Capital Expenditures for Q4 2024 stood at -$34000.0, down from $170000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $4.1 million in Q2 2020, with the low at -$6.0 million in Q4 2020.
- The 5-year median for Capital Expenditures is $290500.0 (2023), against an average of $293950.0.
- The sharpest annual moves came in 2020 and 2024: Capital Expenditures surged 93750.0% in 2020, then plunged 361.54% in 2024.
- NextCure's Capital Expenditures stood at -$6.0 million in 2020, then jumped by 113.65% to $825000.0 in 2021, then increased by 4.85% to $865000.0 in 2022, then sank by 98.5% to $13000.0 in 2023, then sank by 361.54% to -$34000.0 in 2024.
- Business Quant data shows NXTC's Capital Expenditures at -$34000.0 in Q4 2024, $170000.0 in Q3 2024, and $301000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -34,000.00 |
| Dec 31, 2024 | -34,000.00 |
| Sep 30, 2024 | 170,000.00 |
| Sep 30, 2024 | 170,000.00 |
| Jun 30, 2024 | 301,000.00 |
| Jun 30, 2024 | 301,000.00 |
| Mar 31, 2024 | 37,000.00 |
| Mar 31, 2024 | 37,000.00 |
| Dec 31, 2023 | 13,000.00 |
| Dec 31, 2023 | 13,000.00 |
| Sep 30, 2023 | 279,000.00 |
| Sep 30, 2023 | 279,000.00 |
| Jun 30, 2023 | 280,000.00 |
| Jun 30, 2023 | 280,000.00 |
| Mar 31, 2023 | 248,000.00 |
| Mar 31, 2023 | 248,000.00 |
| Dec 31, 2022 | 865,000.00 |
| Dec 31, 2022 | 865,000.00 |
| Sep 30, 2022 | 532,000.00 |
| Sep 30, 2022 | 532,000.00 |